Sign In
Buy PGEN
$6.27
+0.330 (+5.56%)
At Close: Jul 31, 2026
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
10:40pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) Q1 2026 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates
06:36pm, Wednesday, 13'th May 2026
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to a loss of $0.07 per share a year ago.
Precigen Reports First Quarter 2026 Financial Results and Business Updates
04:05pm, Wednesday, 13'th May 2026
PAPZIMEOS™ launch gaining strong momentum with $21.6 million in net product revenue in the first quarter of 2026 reflecting broad-based uptake across the US Patient hub enrollment continues to gain
Precigen to Announce First Quarter 2026 Financial Results and Provide Business Updates on May 13
04:05pm, Thursday, 07'th May 2026
GERMANTOWN, Md., May 7, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
Precigen Reports 'Robust Uptake' of New Drug for Rare Respiratory Disease; First Quarter Revenue Expected to Top $18 Million
07:00am, Tuesday, 07'th Apr 2026
Plans Underway to Expand Use to Pediatrics, Patient Redosing and European Approval Meg Flippin, Benzinga Staff Writer GERMANTOWN, MD / ACCESS Newswire / April 7, 2026 / Precigen Inc. (NASDAQ:PGEN), a
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
01:32am, Wednesday, 01'st Apr 2026
Precigen, Inc. (PGEN) Discusses Launch and Differentiation of PAPZIMEOS Immunotherapy for Adult RRP Transcript
Precigen to Participate in a Fireside Chat with H.C. Wainwright on March 31
08:30am, Monday, 30'th Mar 2026
GERMANTOWN, Md., March 30, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to improve
Precigen (NASDAQ:PGEN) Shares Gap Up on Analyst Upgrade
01:23am, Friday, 27'th Mar 2026
Precigen, Inc. (NASDAQ: PGEN - Get Free Report) gapped up prior to trading on Thursday after Citizens Jmp raised their price target on the stock from $8.00 to $9.00. The stock had previously closed at
Precigen: The Best Potential Blockbuster You've Never Heard Of (Your ENT Has)
01:57pm, Thursday, 26'th Mar 2026
Precigen maintains a Buy rating as Papzimeos' strong launch and FDA approval signal blockbuster potential, with Q1 revenues expected to exceed $18M. PGEN's management guides for cash flow breakeven in
These Analysts Boost Their Forecasts On Precigen Following Q4 Results
12:08pm, Thursday, 26'th Mar 2026
Precigen, Inc. (NASDAQ: PGEN) reported mixed results for the fourth quarter on Wednesday.
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
06:56pm, Wednesday, 25'th Mar 2026
Precigen, Inc. (PGEN) Q4 2025 Earnings Call Transcript
Precigen, Inc. (PGEN) Reports Q4 Loss, Lags Revenue Estimates
06:37pm, Wednesday, 25'th Mar 2026
Precigen, Inc. (PGEN) came out with a quarterly loss of $0.01 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.04 per share a year ago.
Precigen Reports Full Year 2025 Financial Results and Business Updates
04:05pm, Wednesday, 25'th Mar 2026
Precigen transitioned to a commercial stage company with the US approval of PAPZIMEOS™ (zopapogene imadenovec-drba), the first-and-only FDA-approved treatment for adults with RRP, in August 2025 PAP
Precigen to Announce Full Year 2025 Financial Results and Provide Business Updates on March 25
04:05pm, Wednesday, 11'th Mar 2026
GERMANTOWN, Md., March 11, 2026 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a commercial-stage biopharmaceutical company specializing in the advancement of innovative precision medicines to impro
Precigen, Inc. (NASDAQ:PGEN) Given Average Rating of “Hold” by Brokerages
04:46am, Saturday, 07'th Mar 2026
Shares of Precigen, Inc. (NASDAQ: PGEN - Get Free Report) have been assigned a consensus recommendation of "Hold" from the seven research firms that are covering the stock, Marketbeat.com reports. Two
